Long-Term PFS Benefit With Olaparib in nonBRCA-Mutant Ovarian Cancer More Likely With HRD Positivity
March 18th 2022Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.
Adding Nivolumab to Chemotherapy Improves Outcomes in Resectable NSCLC
June 7th 2021The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Neratinib Plus Fulvestrant Combination Does Not Meet Efficacy Criteria for Metastatic Breast Cancer
April 15th 2021The clinical benefit rate of the neratinib plus fulvestrant combination treatment did not meet the predefined efficacy threshold, but was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer.